Comparative Pharmacology
Head-to-head clinical analysis: KANAMYCIN versus NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KANAMYCIN versus NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE.
KANAMYCIN vs NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting protein synthesis.
Neomycin and polymyxin B sulfates are aminoglycoside and polypeptide antibiotics, respectively, that inhibit bacterial protein synthesis and disrupt bacterial cell membrane integrity. Dexamethasone is a corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis.
15 mg/kg/day IM or IV in divided doses every 12 hours. Maximum daily dose: 1.5 g.
Ophthalmic: 1-2 drops in affected eye(s) every 3-4 hours; severe infections: 1-2 drops every 1-2 hours, then taper. Otic: 3-4 drops in affected ear(s) 3-4 times daily.
None Documented
None Documented
Clinical Note
moderateKanamycin + Digoxin
"The serum concentration of Digoxin can be decreased when it is combined with Kanamycin."
Clinical Note
moderateKanamycin + Digitoxin
"The serum concentration of Digitoxin can be decreased when it is combined with Kanamycin."
Clinical Note
moderateKanamycin + Deslanoside
"The serum concentration of Deslanoside can be decreased when it is combined with Kanamycin."
Clinical Note
moderateKanamycin + Acetyldigitoxin
Terminal elimination half-life is 2-4 hours in patients with normal renal function (creatinine clearance >80 mL/min). In anuria, half-life may extend to 50-100 hours, necessitating dose adjustment based on renal function.
Neomycin: 2-3 hours (IM/IV, if absorbed); Polymyxin B: 6-7 hours; Dexamethasone: 3-4.5 hours. Clinically, neomycin's half-life is not relevant due to minimal absorption; polymyxin B prolonged in renal impairment; dexamethasone CNS effect lasts > half-life.
Primarily renal excretion via glomerular filtration; approximately 80-90% of administered dose is excreted unchanged in urine within 24 hours. Biliary/fecal excretion is minimal (<1%).
Neomycin: ~99% of oral dose eliminated unchanged in feces; <1% absorbed renally excreted. Polymyxin B: ~60% renal elimination of absorbed fraction; remainder non-renal via biliary/fecal. Dexamethasone: ~65% renal as metabolites, <10% unchanged; ~35% fecal.
Category C
Category A/B
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic
"The serum concentration of Acetyldigitoxin can be decreased when it is combined with Kanamycin."